Serum IL-1 beta predicts de novo hepatitis B virus reactivation during direct-acting antiviral therapy for hepatitis C, not during anti-cancer/immunosuppressive therapy

Kawagishi, Naoki; Suda, Goki; Sakamori, Ryotaro; Matsui, Takeshi; Onozawa, Masahiro; Yang, Zijian; Yoshida, Sonoe; Ohara, Masatsugu; Kimura, Megumi; Kubo, Akinori; Maehara, Osamu; Fu, Qingjie; Hosoda, Shunichi; Tokuchi, Yoshimasa; Suzuki, Kazuharu; Nakai, Masato; Sho, Takuya; Morikawa, Kenichi; Natsuizaka, Mitsuteru; Ogawa, Koji; Sakai, Hajime; Ohnishi, Shunsuke; Baba, Masaru; Takehara, Tetsuo; Sakamoto, Naoya

Serum IL-1 beta predicts de novo hepatitis B virus reactivation during direct-acting antiviral therapy for hepatitis C, not during anti-cancer/immunosuppressive therapy

Kawagishi, Naoki; Suda, Goki; Sakamori, Ryotaro et al.

Scientific reports, 2022, 12(1), 16800

Permalink : https://hdl.handle.net/2115/87372

このアイテムのアクセス数:379件（2026-08-20 00:52 集計）

閲覧可能ファイル

ファイル	フォーマット	サイズ	閲覧回数	説明
https://doi.org/10.1038/s41598-022-21315-z			11

論文情報

ファイル出力 EndNote Basic出力 Mendeley出力

アクセス権	open access
URI	https://hdl.handle.net/2115/87372
タイトル	Serum IL-1 beta predicts de novo hepatitis B virus reactivation during direct-acting antiviral therapy for hepatitis C, not during anti-cancer/immunosuppressive therapy
著者	Kawagishi, Naoki ; Suda, Goki ; Sakamori, Ryotaro ; Matsui, Takeshi ; Onozawa, Masahiro ; Yang, Zijian ; Yoshida, Sonoe ; Ohara, Masatsugu ; Kimura, Megumi ; Kubo, Akinori ; Maehara, Osamu ; Fu, Qingjie ; Hosoda, Shunichi ; Tokuchi, Yoshimasa ; Suzuki, Kazuharu ; Nakai, Masato ; Sho, Takuya ; Morikawa, Kenichi ; Natsuizaka, Mitsuteru ; Ogawa, Koji ; Sakai, Hajime ; Ohnishi, Shunsuke ; Baba, Masaru ; Takehara, Tetsuo ; Sakamoto, Naoya
著者名 Kawagishi, Naoki
e-Rad_Researcher 20447460 著者名 Suda, Goki
著者名 Sakamori, Ryotaro
著者名 Matsui, Takeshi
e-Rad_Researcher 70455632 著者名 Onozawa, Masahiro
著者名 Yang, Zijian
著者名 Yoshida, Sonoe
著者名 Ohara, Masatsugu
著者名 Kimura, Megumi
著者名 Kubo, Akinori
著者名 Maehara, Osamu
著者名 Fu, Qingjie
著者名 Hosoda, Shunichi
著者名 Tokuchi, Yoshimasa
著者名 Suzuki, Kazuharu
著者名 Nakai, Masato
著者名 Sho, Takuya
著者名 Morikawa, Kenichi
著者名 Natsuizaka, Mitsuteru
e-Rad_Researcher 20735188 著者名 Ogawa, Koji
著者名 Sakai, Hajime
著者名 Ohnishi, Shunsuke
著者名 Baba, Masaru
著者名 Takehara, Tetsuo
e-Rad_Researcher 10334418 著者名 Sakamoto, Naoya
言語	英語
発行日	2022-10-07
出版者	Nature Portfolio
収録物名	Scientific reports
巻(号)	12(1)
ページ	16800
抄録	De novo hepatitis B virus (HBV) reactivation occurs during direct-acting antiviral (DAA) treatment in hepatitis C virus (HCV)-infected patients with resolved HBV infection. We evaluated the predictive factors, mechanical insight, and differences of cytokine levels during anti-cancer/immunosuppressive and DAA. Eleven, 35, and 19 HCV-infected patients with previous HBV infection with HBV reactivation during DAA treatment, previous HBV infection without HBV reactivation during DAA treatment, and without HBV infection resolution receiving DAA treatment, respectively, were enrolled. Clinical data and baseline cytokine levels were analyzed. Low baseline serum interleukin (IL)-1 beta levels predicted de novo HBV reactivation during DAA treatment (odds ratio: 47.6, 95% confidence interval: 6.94-333.3). HCV-infected patients with the IL-1 beta gene single nucleotide polymorphism rs16944 AA allele had significantly higher IL-1 beta levels; no HCV-infected patient with the IL-1 beta AA allele experienced HBV reactivation during DAA treatment. Compared to HCV-infected patients with HBV infection resolution, non-HCV infected patients with or without HBV reactivation during anti-cancer/immunosuppressive therapy or bone marrow transplantation had remarkably lower baseline IL-1 beta levels. Low IL-1 beta levels were not associated with HBV reactivation. IL-1 beta levels before DAA for HCV-infected patients with resolved HBV infection could predict HBV reactivation during DAA treatment.
資源タイプ	学術雑誌論文
出版タイプ	Version of Record
PISSN	2045-2322
関連情報 (isIdenticalTo)	出版社版DOI https://doi.org/10.1038/s41598-022-21315-z